LivaNova PLC Ordinary Shares - LIVN STOCK NEWS

LivaNova PLC (Nasdaq: LIVN) reported Q1 2022 results with worldwide sales of $240.2 million, down 3.0% year-over-year. Excluding divested Heart Valves, sales increased 6.2%. U.S. GAAP diluted earnings per share were $0.06, while adjusted EPS reached $0.48. Key advancements included the implantation of 250 unipolar depression patients in ongoing trials and the acquisition of ALung Technologies. LivaNova projects 2022 sales growth between 3-5% and adjusted EPS of $2.50 to $2.80. Despite macroeconomic challenges, growth was noted in Cardiopulmonary and Neuromodulation segments.

LivaNova PLC (NASDAQ: LIVN) announced the launch of the Essenz Patient Monitor, designed to enhance clinical efficiency during cardiopulmonary bypass procedures. The monitor has received FDA 510(k) clearance and CE Mark, enabling its initial deployment in select U.S. and European hospitals. Developed through collaboration with perfusionists, it offers advanced data display and decision-making support. Future stages will include the complete Essenz Perfusion System, aimed at improving patient outcomes through goal-directed perfusion strategies.

LivaNova, a global medical technology company, will hold a conference call on May 4, 2022, at 1 p.m. London time to discuss its first-quarter 2022 results. The results will be released prior to the call. Interested parties can access the audiocast on the company's website or by telephone. LivaNova, headquartered in London, focuses on innovative medical technologies to improve patient care, with a workforce of about 3,000 and operations in over 100 countries. A replay of the call will be available for 90 days.

LivaNova PLC (NASDAQ: LIVN) announces a significant milestone in its RECOVER clinical study, implanting the 250th patient with treatment-resistant unipolar depression. This trial, emphasizing the safety and efficacy of VNS Therapy, is critical due to the high prevalence of treatment-resistant depression worldwide. The RECOVER study, initiated in September 2019, aims to enroll up to 1,000 patients. Interim analyses will assess success probabilities, impacting potential Medicare reimbursement for VNS Therapy. A successful outcome could enhance access to LivaNova's Symmetry device for patients globally.

LivaNova PLC has announced the first patient implanted in its IDE clinical study, OSPREY, aimed at evaluating the effectiveness of its aura6000™ System for treating moderate to severe obstructive sleep apnea (OSA). Conducted at around 20 sites in the U.S., the study plans to enroll up to 150 patients. The aura6000 System is designed to stimulate the hypoglossal nerve and may offer an alternative to CPAP therapy, which many patients find restrictive.

LivaNova PLC (Nasdaq: LIVN) reported a modest 0.2% increase in Q4 2021 worldwide sales from continuing operations, totaling $270.1 million. Excluding the divested Heart Valves business, sales rose by 10.1%. Adjusted diluted earnings per share (EPS) was $0.57, down from $0.70 in Q4 2020. For full-year 2021, total sales reached $1.035 billion, with a 10.8% increase year-over-year. LivaNova anticipates 2022 sales growth of 3-5% and adjusted EPS between $2.50-$2.80. Notably, the company is currently involved in a significant litigation case in Italy.

LivaNova PLC (NASDAQ: LIVN) is set to host a conference call on February 23, 2022, at 1 p.m. London time to discuss its fourth-quarter and full-year 2021 results. The results will be released prior to the call. Investors can access the call via audiocast on the LivaNova website or by phone. The company emphasizes its commitment to innovative medical technologies aimed at improving patient outcomes worldwide. For more details, visit www.livanova.com.

LivaNova PLC (NASDAQ:LIVN), a leader in medical technology, will participate in the American Epilepsy Society Annual Meeting from December 3-7 in Chicago. The company plans to present seven scientific posters highlighting its VNS Therapy System, which has been effective in treating drug-resistant epilepsy for over 25 years. Presentations will cover patient profiles, healthcare costs, and optimal treatment strategies. LivaNova demonstrates its dedication to neuromodulation research and collaboration with independent investigators to improve outcomes for epilepsy patients.

LivaNova PLC (LIVN) announced its participation in the 4th International Brain Stimulation Conference from December 6-9 in Charleston, S.C. The company will showcase its advancements in VNS Therapy^® for treatment-resistant depression. LivaNova is conducting the RECOVER study to evaluate VNS Therapy's effectiveness for difficult-to-treat depression.